(0.05%) 5 519.50 points
(0.12%) 39 890 points
(0.12%) 19 775 points
(-0.02%) $81.61
(0.43%) $2.82
(-0.22%) $2 339.30
(0.25%) $29.60
(0.50%) $1 006.80
(0.07%) $0.932
(-0.12%) $10.52
(-0.01%) $0.788
(-0.85%) $87.25
-0.17% $ 36.06
Live Chart Being Loaded With Signals
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer...
Stats | |
---|---|
Dzisiejszy wolumen | 1.10M |
Średni wolumen | 793 330 |
Kapitalizacja rynkowa | 2.67B |
EPS | $-1.180 ( Q1 | 2024-05-02 ) |
Następna data zysków | ( $-1.170 ) 2024-07-31 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-7.00 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0250 (0.07%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-03 | Islam Saqib | Sell | 33 240 | Common Stock |
2024-06-03 | Islam Saqib | Sell | 8 760 | Common Stock |
2024-06-03 | Islam Saqib | Sell | 6 600 | Common Stock |
2024-06-03 | Islam Saqib | Sell | 400 | Common Stock |
2024-06-03 | Hambleton Julie | Sell | 2 946 | Common Stock |
INSIDER POWER |
---|
17.73 |
Last 99 transactions |
Buy: 1 648 575 | Sell: 1 984 594 |
Wolumen Korelacja
Springworks Therapeutics Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
TNYA | 0.843 |
TIL | 0.837 |
SLN | 0.831 |
IDYA | 0.827 |
AVIR | 0.823 |
CHSCL | 0.822 |
IMNM | 0.82 |
EOLS | 0.811 |
RLMD | 0.801 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Springworks Therapeutics Korelacja - Waluta/Towar
Springworks Therapeutics Finanse
Annual | 2023 |
Przychody: | $5.45M |
Zysk brutto: | $5.03M (92.25 %) |
EPS: | $-5.15 |
FY | 2023 |
Przychody: | $5.45M |
Zysk brutto: | $5.03M (92.25 %) |
EPS: | $-5.15 |
FY | 2022 |
Przychody: | $6.15M |
Zysk brutto: | $4.25M (69.16 %) |
EPS: | $-5.14 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-4.02 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Springworks Therapeutics
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej